Market Cap | 354.26M | P/E | - | EPS this Y | 11.10% | Ern Qtrly Grth | - |
Income | -64.4M | Forward P/E | -9.21 | EPS next Y | 50.00% | 50D Avg Chg | -3.00% |
Sales | 171.36M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 41.00% |
Dividend | N/A | Price/Book | 11.78 | EPS next 5Y | - | 52W High Chg | -16.00% |
Recommedations | 1.50 | Quick Ratio | 1.71 | Shares Outstanding | 148.26M | 52W Low Chg | 166.00% |
Insider Own | 2.69% | ROA | -8.55% | Shares Float | 143.83M | Beta | 1.29 |
Inst Own | 41.94% | ROE | -617.16% | Shares Shorted/Prior | 11.41M/11.09M | Price | 2.58 |
Gross Margin | 82.90% | Profit Margin | -37.58% | Avg. Volume | 1,188,125 | Target Price | 4.58 |
Oper. Margin | -35.05% | Earnings Date | Aug 8 | Volume | 669,522 | Change | -4.09% |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
HC Wainwright & Co. | Buy | May 31, 24 |
Piper Sandler | Overweight | May 10, 24 |
Oppenheimer | Outperform | Mar 28, 24 |
HC Wainwright & Co. | Buy | Mar 7, 24 |
HC Wainwright & Co. | Buy | Nov 13, 23 |
Piper Sandler | Overweight | Nov 10, 23 |
Craig-Hallum | Buy | Aug 28, 23 |
HC Wainwright & Co. | Buy | Aug 9, 23 |
HC Wainwright & Co. | Buy | May 10, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Schmid John P. | Director Director | Nov 16 | Buy | 1.51 | 6,500 | 9,815 | 6,500 | 11/17/23 |
Shannon John Patrick Jr | See Remarks See Remarks | Nov 17 | Buy | 1.638 | 30,769 | 50,400 | 1,408,575 | 11/17/23 |
Edick Paul R | See Remarks See Remarks | Aug 09 | Buy | 2.3794 | 10,000 | 23,794 | 2,288,064 | 08/09/23 |